Sarissa Capital Management LP
Q1 2014 13F-HR Holdings
Net value change ($000)
+23,406
(8.8%)
New positions
6
Sold out positions
3
Turnover %
18.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Bio-Reference Laboratories Inc. | 28,171 | 386.6% |
| ARIAD PHARMACEUTICALS INC | 14,880 | 18.2% |
| DGX | 7,410 | 19.8% |
| LH | 3,715 | NEW |
| Keenova Therapeutics plc | 2,798 | 19.1% |
| MRK | 2,688 | 13.4% |
| Intra-Cellular Therapies, Inc. | 2,303 | NEW |
| ONCONOVA THERAPEUTICS INC | 2,219 | NEW |
| ENTA | 2,000 | NEW |
| Kindred Biosciences, Inc. | 1,887 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| BMY | -13,288 | -100.0% |
| ABBV | -13,203 | -100.0% |
| PFE | -12,558 | -100.0% |
| VIVUS INC | -8,082 | -34.6% |
| AVEO PHARMACEUTICALS, INC. | -887 | -18.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|